NANO.PA AI Price Prediction

Track NANO.PA's AI-powered predictions, market trends, and investment insights.

NANO.PA Sentiment NANO.PA StockTwits NANO.PA Reddit

Mock Tradesimulated, no real money

You don't hold NANO.PA in your mock portfolio yet.

NANO.PA AI Price Prediction

Track NANO.PA's AI-powered predictions, market trends, and investment insights.

NANO.PA Sentiment NANO.PA StockTwits NANO.PA Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)-3.6%

Price (7d)-17.7%

Volume vs avg0.7x

Volatility vs normal0.8x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

No flags triggered by these checks.

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~€30.14 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

NANO.PA AI Stock Analysis

Financial Performance

bearish

Nanobiotix S.A. is currently loss‑making, as indicated by its negative EPS and PE ratio. The lack of profitability suggests that the investment thesis is driven more by future growth expectations and pipeline potential than by current financial strength. Until there is a clear path to positive earnings, the financial profile remains high risk.

Negative EPS of -0.50 indicates the company is not currently generating net income and is likely burning cash to fund operations and R&D.
A PE ratio of -88.20 underscores that the stock is not supported by current earnings and is instead priced on expectations of future success, typical of early‑stage or clinical‑stage biotech.
Absent evidence of improving margins or a near‑term inflection to profitability, the financial picture is fundamentally weak and exposes shareholders to dilution and financing risk.

Stock Price & Technicals

bullish

The stock’s recent price action is strongly positive, with a 58.2% gain over the last month and a price well above its 200‑day moving average. This suggests strong upward momentum and a favorable technical backdrop, albeit with elevated volatility and potential for pullbacks. The move appears momentum‑driven rather than supported by earnings.

Current price of €44.10 is significantly above the 200‑day moving average of €19.48, indicating a strong uptrend and positive long‑term momentum.
A 58.2% gain in the last month points to aggressive recent buying, often associated with catalysts such as clinical news, partnerships, or speculative interest.
Given the sharp move and lack of earnings support, traditional momentum indicators like RSI (not provided, but likely elevated) may be in or near overbought territory, implying higher short‑term downside risk even within a bullish trend.

Alternative Data Signals

neutral

Alternative data for Nanobiotix S.A. shows modest and relatively slow growth in digital presence and hiring, with small follower bases and low web traffic. These signals do not point to a strong commercial ramp or broadening retail/investor awareness yet. Overall, they neither strongly confirm nor contradict the bullish technical picture.

Estimated web traffic of 8,481 visitors per month is relatively low, suggesting limited current commercial scale and modest investor or patient awareness online.
Only 1 job opening with 0.0% month‑over‑month growth indicates no visible hiring surge, implying the company is not in a rapid expansion phase in terms of headcount.
Social media presence is small (e.g., 3,852 followers on Twitter/X, 80 on Instagram, 36 on Facebook, 240 on YouTube) with only slight growth over the last 90 days, pointing to gradual rather than explosive engagement or brand visibility.

Conclusion

neutral

Nanobiotix S.A. presents a classic high‑risk, high‑reward biotech profile: technically strong and momentum‑driven, but underpinned by weak current financials and modest alternative data signals. The recent price surge and position well above the 200‑day moving average are bullish from a trading standpoint, yet the negative earnings and limited evidence of scaling operations temper the outlook. Overall, the setup appears neutral, skewed toward speculative rather than fundamentally grounded upside.

Bullish technical momentum contrasts with bearish fundamentals, suggesting the stock is driven by expectations and catalysts rather than earnings strength.
Alternative data does not yet show strong signs of commercial traction or rapidly expanding awareness, reinforcing that this is primarily a speculative, event‑driven biotech story rather than a mature growth play.

AI Score

Hold

Alternative4

Fundamental2

Technical7

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold NANO.PA in your mock portfolio yet.